Acceptability of Cyltezo® Pen Among Patients and Healthcare Professionals

Study Objectives

The research aimed to assess:

1. Usability and ease of handling.
2. Comfort and convenience of home use.
3. Perceptions of the pen’s safety features.
4. Overall satisfaction and willingness to adopt the Cyltezo pen.

Methods

The study included 297 participants divided into three groups:

• 98 existing Humira Pen users.
• 100 biologics autoinjector-naïve patients.
• 99 healthcare professionals.

Participants simulated the use of the Cyltezo pen on injection pads during moderated interviews. Their opinions were captured using a validated questionnaire based on Likert-type scales. Statistical analysis, including binomial tests, was used to assess top-two rating percentages for various parameters.

Key Findings

The study demonstrated overwhelming positive feedback across all groups. Key results include:

1. Ease of Use:
   • Nearly 90% of participants found the Cyltezo pen “easy” or “very easy” to use, handle, and learn.
   • The design of the pen contributed to user confidence, particularly for biologics autoinjector-naïve individuals.
2. Convenience and Comfort:
   • Approximately 90% of users rated the pen as “very” or “extremely” convenient for home use.
   • Around 80% of participants found the Cyltezo pen “very” or “extremely” comfortable to handle.
3. Safety Features:
   • Over 90% of respondents expressed satisfaction with the pen’s safety features, highlighting its role in reducing anxiety during injections.
4. Overall Satisfaction:
   • More than 90% of participants reported being “satisfied” or “very satisfied” with the pen’s usability, handling, and safety.
   • Nearly 90% of participants indicated they were “very” or “extremely” open to adopting the Cyltezo pen for regular use.

Implications for Autoinjector Devices

The Cyltezo pen’s strong performance highlights the importance of user-centric design in drug delivery devices. By addressing key concerns such as ease of use, safety, and convenience, the Cyltezo pen meets the needs of both patients and healthcare professionals. For autoinjector-naïve individuals, the intuitive design reduces barriers to adoption, while experienced users appreciate the device’s reliability and comfort.

Conclusions

This study demonstrates that the Cyltezo pen provides a positive user experience, with high acceptability across all groups surveyed. Its usability, safety, and convenience position it as a highly effective option for the administration of adalimumab-adbm. These findings reinforce the Cyltezo pen’s potential to enhance patient adherence and satisfaction, making it a valuable tool in managing chronic inflammatory conditions.